The estimated Net Worth of Frontier, Llcgates William ... is at least $8.15 Milion dollars as of 21 December 2021. Frontier William owns over 1,268,619 units of Exicure Inc stock worth over $7,850,290 and over the last 3 years Frontier sold XCUR stock worth over $304,469.
Frontier has made over 1 trades of the Exicure Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Frontier sold 1,268,619 units of XCUR stock worth $304,469 on 21 December 2021.
The largest trade Frontier's ever made was selling 1,268,619 units of Exicure Inc stock on 21 December 2021 worth over $304,469. On average, Frontier trades about 1,268,619 units every 0 days since 2021. As of 21 December 2021 Frontier still owns at least 5,064,703 units of Exicure Inc stock.
You can see the complete history of Frontier William stock trades at the bottom of the page.
Frontier's mailing address filed with the SEC is 2365 CARILLON POINT2365 CARILLON POINT, , KIRKLANDKIRKLAND, WAWA, 9803398033.
Over the last 6 years, insiders at Exicure Inc have traded over $4,850,172 worth of Exicure Inc stock and bought 7,217,940 units worth $10,705,021 . The most active insiders traders include Timothy P Walbert, Co., Ltd. Dgp oraz Usa, Inc. Cbi. On average, Exicure Inc executives and independent directors trade stock every 90 days with the average trade being worth of $928,360. The most recent stock trade was executed by Co., Ltd. Dgp on 29 February 2024, trading 3,400,000 units of XCUR stock currently worth $4,488,000.
exicure, formerly aurasense therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. our 3-dimensional, spherical nucleic acid (sna™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. our lead programs address diseases from inflammatory disorders to oncology. sna constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. sna constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. moreover, snas can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
Exicure Inc executives and other stock owners filed with the SEC include: